We are live on ! Find out more
BOCH

Blue Owl Capital Holdings Portfolio holdings

AUM $372M
1-Year Est. Return 78.25%
This Fund
S&P 500
This Quarter Est. Return
+27.71%
1 Year Est. Return
+78.25%
3 Year Est. Return
+112.77%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$322M
AUM Growth
+$12.3M
Cap. Flow
-$21.1M
Cap. Flow %
-6.55%
Top 10 Hldgs %
61.66%
Holding
80
New
8
Increased
8
Reduced
12
Closed
8

Top Buys

Rank Stock Value
1
ROIV icon
Roivant Sciences
ROIV
+$12.2M
2
RARE icon
Ultragenyx Pharmaceutical
RARE
+$5.01M
3
DELL icon
Dell
DELL
+$4.09M
4
LRMR icon
Larimar Therapeutics
LRMR
+$3.47M
5
IMRX icon
Immuneering
IMRX
+$2.85M

Top Sells

Rank Stock Value
1
TRML
Tourmaline Bio
TRML
+$15.9M
2
NCDL icon
Nuveen Churchill Direct Lending
NCDL
+$15.2M
3
TEM
Tempus AI
TEM
+$5.09M
4
MLYS icon
Mineralys Therapeutics
MLYS
+$5.08M
5
TNGX icon
Tango Therapeutics
TNGX
+$4.7M

Sector Composition

Rank Sector Weight
1 Healthcare 56.77%
2 Financials 22.9%
3 Technology 12.32%
4 Consumer Discretionary 7.01%
5 Energy 0.3%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MLYS icon
26
Mineralys Therapeutics
MLYS
$2.41B
$3.83M 1.19%
100,944
-235,000
-70% -$5.08M
CMPS
27
Compass Pathways
CMPS
$1.83B
$3.47M 1.08%
604,914
+375,000
+163% +$1.69M
ADCT icon
28
ADC Therapeutics
ADCT
$144M
$2.93M 0.91%
733,568
– –
NU icon
29
Nu Holdings
NU
$66.9B
$2.78M 0.86%
+173,873
New +$2.43M
MREO
30
Mereo BioPharma
MREO
$47.3M
$2.58M 0.8%
+1,250,000
New +$2.3M
ELDN icon
31
Eledon Pharmaceuticals
ELDN
$285M
$2.54M 0.79%
979,912
-350,000
-26% -$1.02M
ACLX
32
DELISTED
Arcellx
ACLX
$2.2M 0.68%
+26,823
New +$1.93M
KALV
33
DELISTED
KalVista Pharmaceuticals
KALV
$1.52M 0.47%
+125,000
New +$1.73M
FLD
34
Fold Holdings
FLD
$24.9M
$1.45M 0.45%
856,632
– –
NIOBW
35
NioCorp Developments Ltd Warrant
NIOBW
$79.3M
$1.01M 0.31%
546,442
– –
TNGX icon
36
Tango Therapeutics
TNGX
$4.41B
$1M 0.31%
119,416
-695,000
-85% -$4.7M
EPD icon
37
Enterprise Products Partners
EPD
$81.7B
$978K 0.3%
31,290
– –
GTLB icon
38
GitLab
GTLB
$6.58B
$557K 0.17%
+12,352
New +$565K
SHFS icon
39
SHF Holdings
SHFS
$1.13M
$543K 0.17%
75,897
– –
TTAN
40
ServiceTitan Inc
TTAN
$8.19B
$500K 0.16%
4,954
-6,396
-56% -$702K
MRKR icon
41
Marker Therapeutics
MRKR
$18.7M
$495K 0.15%
554,250
– –
RZLVW
42
Rezolve AI Warrants
RZLVW
$5.64M
$470K 0.15%
292,930
-183,755
-39% -$212K
AMOD
43
Alpha Modus Holdings
AMOD
$22.1M
$454K 0.14%
9,852
– –
CAH icon
44
Cardinal Health
CAH
$55.4B
$270K 0.08%
1,718
– –
PIPR icon
45
Piper Sandler
PIPR
$5.29B
$211K 0.07%
+2,428
New +$198K
SLND.WS icon
46
Southland Holdings Warrants
SLND.WS
$166K 0.05%
860,302
– –
AMODW
47
Alpha Modus Holdings Warrant
AMODW
$316K
$144K 0.04%
1,854,665
– –
BGLWW
48
Blue Gold Ltd Warrant
BGLWW
$736K
$80.1K 0.02%
175,000
– –
OPTXW icon
49
Syntec Optics Holdings Warrant
OPTXW
$19.2M
$70K 0.02%
803,132
– –
BKSY.WS icon
50
BlackSky Technology Inc Warrants
BKSY.WS
$65.9K
$59K 0.02%
350,000
– –
1
2
3 4

Similar funds

PC
Promethos Capital Boston, Massachusetts $372M AUM 23.19% 1-Year Est. Return
GIP
Gavilan Investment Partners Burlingame, California $372M AUM 6.04% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return
SAAM
Solus Alternative Asset Management Summit, New Jersey $372M AUM 45.33% 1-Year Est. Return
KP
Kiltearn Partners Edinburgh, United Kingdom $372M AUM 18.16% 1-Year Est. Return
TCM
Thomist Capital Management Houston, Texas $371M AUM 77.62% 1-Year Est. Return
PAA
Peregrine Asset Advisers Portland, Oregon $371M AUM 41.36% 1-Year Est. Return
JC
Joho Capital New York $373M AUM 18.89% 1-Year Est. Return

Blue Owl Capital Holdings's Q3 2025 Portfolio in Review

As of Q3 2025, Blue Owl Capital Holdings held 80 positions worth $322M, up 4% from $310M the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Blue Owl Capital Holdings withdrew a net $21.1M in Q3 2025, closing 8 positions and reducing 12 holdings. Its most notable exit was Tourmaline Bio, an estimated $15.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 57% of assets, up from 51% a quarter earlier, followed by Financials and Technology.

Against the trend, Blue Owl Capital Holdings opened a new position in Roivant Sciences worth $15M.

  • Blue Owl Capital Holdings's largest Q3 2025 buy was Roivant Sciences: 988,249 shares worth $15M.
  • Blue Owl Capital Holdings added most to Ultragenyx Pharmaceutical in Q3 2025, an estimated $5.01M increase.
  • Blue Owl Capital Holdings's biggest Q3 2025 reduction was Nuveen Churchill Direct Lending, cutting an estimated $15.2M.
  • Blue Owl Capital Holdings fully exited Tourmaline Bio in Q3 2025, selling an estimated $15.9M.
  • Blue Owl Capital Holdings's ten largest holdings make up 62% of its $322M portfolio in Q3 2025.
  • Blue Owl Capital Holdings opened 8 new positions and closed 8 in Q3 2025.
  • Blue Owl Capital Holdings's portfolio value rose 4% quarter-over-quarter to $322M.

Based on Blue Owl Capital Holdings's 13F filing for Q3 2025, filed 12 Nov 2025.